Nutrition Ameliorates the Muscle Loss of Pre-sarcopenia in Elderly

Chang Gung Memorial Hospital60 enrolled

Overview

This study evaluates the effects of a 12-week leucine-enriched protein supplementation in adults aged 60 years and more. Participants will undergo assessments of muscle mass and function, as well as metabolic profiles in blood, urine, and feces before and after the intervention.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Low Muscle Mass Low Muscle Strength Low Physical Function

Interventions

Participants consume two sachets daily over a 12-week intervention period.DIETARY_SUPPLEMENT

Each 8 g serving provided 35 kcal, comprising 4.1 g of protein, 1 g of fat, and 2.4 g of carbohydrates.

Eligibility

Sex: ALLMin age: 60 YearsMax age: 90 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Willing to provide written informed consent. 2. Participants who attend health check-ups at Songshan District, Taipei City, or at the Wellness Cultural Village, or who have participated in the pilot study. 3. Adults aged 60 years or older, male or female. 4. Able to ambulate independently. 5. Meets at least one of the following sarcopenia criteria: Grip strength: Men \< 28 kg; Women \< 18 kg Gait speed: \< 1.0 m/s Muscle mass (appendicular skeletal muscle mass / height²): Men \< 7.0 kg/m²; Women \< 5.7 kg/m² Exclusion Criteria: 1. Impaired renal function. 2. Allergy or intolerance to protein supplements. 3. Currently undergoing cancer treatment. 4. Autoimmune diseases. 5. Assessed by a physician as unsuitable to participate.

Locations (1)

Chang Gung Memorial Hospital

Taoyuan District, Guishan, Taiwan

Outcomes

Primary Outcomes

Appendicular Skeletal Muscle Index (ASMI)

Muscle mass was assessed using bioelectrical impedance analysis (Tanita MC-780MA). The appendicular skeletal muscle index (ASMI, kg/m2) was calculated as appendicular skeletal muscle mass (ASM, kg) divided by height squared (m²).

Time frame: Baseline and 12 weeks after intervention

Handgrip Strength (HGS)

Functional performance was evaluated by handgrip strength (HGS, kg), measured with a digital hand dynamometer.

Time frame: Baseline and 12 weeks after intervention

Gait speed (m/s)

Gait speed was assessed as the time required to walk a 4 meters, expressed in meters per second (m/s).

Time frame: Baseline and 12 weeks after intervention

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.